GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Cyclically Adjusted PS Ratio

Karo Pharma AB (Karo Pharma AB) Cyclically Adjusted PS Ratio : (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karo Pharma AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Karo Pharma AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Cyclically Adjusted PS Ratio Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karo Pharma AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karo Pharma AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's Cyclically Adjusted PS Ratio falls into.



Karo Pharma AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Karo Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2022 is calculated as:

For example, Karo Pharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=0/118.3836*118.3836
=0.000

Current CPI (Jun. 2022) = 118.3836.

Karo Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201206 0.036 100.352 0.042
201209 0.038 100.467 0.045
201212 0.029 100.403 0.034
201303 0.033 100.416 0.039
201306 0.027 100.206 0.032
201309 0.072 100.544 0.085
201312 0.035 100.541 0.041
201403 0.022 99.788 0.026
201406 0.022 100.432 0.026
201409 0.024 100.161 0.028
201412 0.020 100.225 0.024
201503 0.001 99.950 0.001
201506 0.004 99.995 0.005
201509 0.016 100.228 0.019
201512 0.097 100.276 0.115
201603 0.143 100.751 0.168
201606 0.111 101.019 0.130
201609 0.112 101.138 0.131
201612 0.118 102.022 0.137
201703 0.159 102.022 0.185
201706 0.187 102.752 0.215
201709 0.216 103.279 0.248
201712 0.289 103.793 0.330
201803 0.277 103.962 0.315
201806 0.316 104.875 0.357
201809 0.267 105.679 0.299
201812 0.296 105.912 0.331
201903 0.273 105.886 0.305
201906 0.248 106.742 0.275
201909 0.284 107.214 0.314
201912 0.311 107.766 0.342
202003 0.359 106.563 0.399
202006 0.329 107.498 0.362
202009 0.342 107.635 0.376
202012 0.384 108.296 0.420
202103 0.370 108.360 0.404
202106 0.392 108.928 0.426
202109 0.376 110.338 0.403
202112 0.373 112.486 0.393
202206 0.000 118.384 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karo Pharma AB  (OTCPK:KARBF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Karo Pharma AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (Karo Pharma AB) Business Description

Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire 06-25-2019